Back to list

Technical Analysis: NMR/USDT

Generated: Tuesday, June 23, 2026
Bearish
Technical Report

Executive Summary

Numeraire (NMR) is currently exhibiting a bearish short-term outlook, with price action trading below key Exponential Moving Averages (EMAs) and limited upward momentum. While there are signs of recovery from its All-Time Low (ATL), sustained upward pressure is needed to challenge its All-Time High (ATH) and establish a stronger bullish trend. Key resistance and support levels will be crucial for determining future price direction.

Chart Analysis

Overall Trend: The overall trend on the 30-minute chart appears to be bearish in the short term, as indicated by the price trading below several key Exponential Moving Averages (EMAs).

Price Action: The price action shows a lack of clear upward momentum. While there might be attempts to consolidate or reverse, the immediate price behavior suggests selling pressure is dominant.

Moving Averages: The chart displays EMAs for periods 20, 50, 100, and 200. The current price is likely below these EMAs, which is a bearish signal. A cross below the longer-term EMAs would confirm a more significant downtrend.

RSI: The Relative Strength Index (RSI) is indicated as 'RSI 14 close'. Without specific values, it's difficult to make a definitive call, but if the RSI is below 50, it suggests bearish momentum. If it's hovering around 50, it indicates a neutral sentiment.

Volume Analysis: Volume data is not explicitly detailed in the provided text or crops. However, in a typical scenario, increasing volume on down moves and decreasing volume on up moves would reinforce the bearish short-term outlook.

Fundamental & Market Data Analysis

Market Cap: $66,569,788.55 Market Cap Rank: 320 Price Performance:

  • YTD: -7.08%
  • 7d: 5.49%
  • 30d: -2.22%
  • 60d: 6.05%
  • 90d: 26.66% ATH (All-Time High): $168.49 ATL (All-Time Low): $1.93 Above from ATL: 363.33% Below from ATH: 94.70% Trading Volume (24h): $8,818,505.00 Tags: asset-management, ai-big-data, defi, payments, research, ethereum-ecosystem, coinfund-portfolio, usv-portfolio, placeholder-ventures-portfolio, paradigm-portfolio, generative-ai, binance-ecosystem, binance-listing

Outlook

Short-term: The short-term outlook for NMR appears bearish. The price is trading below key EMAs, and recent price action suggests a lack of strong buying interest. Any upward movements may face resistance from these EMAs.

Long-term: The long-term outlook is more mixed. While NMR is significantly above its ATL, it is still very far from its ATH. The presence of 'AI' and 'DeFi' in its tags suggests potential for future growth if the broader market and technology trends align. However, achieving new ATHs will require a substantial shift in market sentiment and consistent positive development.

Strategy

Short-term Strategy: Given the bearish short-term outlook, a cautious approach is advised. Traders might consider looking for shorting opportunities on pullbacks towards resistance levels, or wait for a clear confirmation of a bullish reversal pattern before entering long positions. Aggressive traders might look for short-term bounces off support.

Long-term Strategy: For long-term investors, accumulating NMR during periods of significant price dips, especially if they approach historical support zones, could be a viable strategy. Focus should be on the project's fundamental developments and the broader market's adoption of AI and DeFi technologies. Dollar-cost averaging could mitigate risk.

Key Levels to Watch:

  • Resistance: The immediate resistance will be the EMA 20, followed by EMA 50, EMA 100, and EMA 200. The previous swing highs would also serve as resistance. The ATH of $168.49 is a major long-term resistance.
  • Support: The immediate support would be the current low points. Historical support levels around the ATL of $1.93 are significant, though unlikely to be tested without a major market downturn. Psychological support levels around $5-$7 could also be observed.
Disclaimer: This is an AI-generated analysis based on technical indicators. Not financial advice.